Blood Centers Seek Action On Assay Standards, Reentry Algorithms
This article was originally published in The Gray Sheet
Executive Summary
There is little incentive in the current regulatory environment for manufacturers to improve the specificity and sensitivity of blood borne pathogen screening assays, American Red Cross Executive Scientific Officer Susan Stramer, PhD, maintained at a Dec. 5 FDA workshop on nucleic acid testing (NAT) in Bethesda, Maryland